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Simvastatin suppresses tissue factor expression and increases
fibrinolytic activity in tumor necrosis factor-–activated
human peritoneal mesothelial cells
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t-PA, PAI-1 and tissue factor expression were prevented bySimvastatin suppresses tissue factor expression and increases
mevalonate and geranylgeraniol (GG), suggesting the involve-fibrinolytic activity in tumor necrosis factor-–activated human
ment of geranylgeranyl-modified intermediates in simvastatin’speritoneal mesothelial cells.
mode of action. Also, simvastatin reduced NF-B– and AP-1–Background. Patients treated with peritoneal dialysis fre-
dependent reporter gene activity in TNF-–treated HT-1080 fi-quently suffer from recurrent peritonitis episodes. During peri-
tonitis, inflammatory mediators are released and a serofibri- brosarcoma cells and reduced the nuclear levels of p50-NF-B,
nous exudate is formed in the peritoneal cavity, which promotes p65-NF-B, and the AP-1 components c-fos and c-jun in HMC.
fibrosis and abdominal adhesion development. Human perito- Conclusion. The HMG-CoA reductase inhibitor simvastatin
neal mesothelial cells (HMC) play a critical role in maintaining is an effective stimulator of the mesothelial fibrinolytic capacity
the intraperitoneal balance between fibrinolysis and coagula- and suppresses the procoagulant activity both under normal
tion by expressing the fibrinolytic enzyme tissue-type plasmino- and inflammatory conditions. Our findings provide a molecular
gen activator (t-PA) and its specific inhibitor, plasminogen explanation for the anti-inflammatory properties of statins in
activator inhibitor-1 (PAI-1) as well as the procoagulant pro- HMC and a rationale for the use of these drugs to protect
tein, tissue factor. peritoneal dialysis patients from peritoneal fibrosis and adhe-
Methods. Cultured HMC were used to examine the effect sion development during bacterial peritonitis.
of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase inhibitor, simvastatin, on the expression of t-PA, PAI-1
and tissue factor after activation of the cells with tumor necrosis
End-stage renal failure patients treated with peritonealfactor- (TNF-). Antigen concentrations in the cell superna-
tants were measured by enzyme-linked immunosorbent assay dialysis suffer a high incidence of bacterial peritonitis.
(ELISA). Northern blot analysis was conducted for mRNA Bacterial infections lead to recruitment of inflammatory
expression. Luciferase reporter gene assays and Western blot cells, which produce inflammatory mediators leading toanalysis in human fibrosarcoma HT1080 cells and HMC were
the development of a serofibrinous exudate. Serial biop-performed to analyze the effect of simvastatin on the transcrip-
sies show that a delayed removal of fibrin is followed bytion factors nuclear factor kappa B (NF-B) and activator
protein-1 (AP-1), which regulate tissue factor gene expression. organization of the fibrin deposits as a result of fibroblast
Results. Incubation of HMC with TNF- resulted in signifi- ingrowth, collagen deposition, and vessel formation [1, 2].
cantly decreased t-PA and increased PAI-1 synthesis. In the pres-
This can cause complications as serious as peritonealence of simvastatin t-PA synthesis in control and TNF-–treated
fibrosis and adhesion development, which are majorcells dose-dependently increased, reaching 5.8-fold and 7.7-
fold higher t-PA levels, respectively, at 5 mol/L simvastatin af- causes of dropout from peritoneal dialysis [2, 3].
ter 48 hours. Simvastatin dose-dependently suppressed PAI-1 Human peritoneal mesothelial cells (HMC), which
production in both control and TNF-–treated cells. At 5 line the peritoneal cavity, play a critical role in main-
mol/L, simvastatin lowered PAI-1 synthesis 3.4-fold and 4.0-
taining the integrity of the peritoneal surface by express-fold, respectively, thereby also completely suppressing the
ing both fibrin-dissolving (fibrinolytic) and fibrin-form-TNF- effect itself. Similarly, simvastatin down-regulated the ex-
pression of tissue factor and also completely opposed the TNF-– ing (procoagulant) factors. A key enzyme in the onset of
induced tissue factor expression. The effects of simvastatin on fibrinolysis is tissue-type plasminogen activator (t-PA),
the activity of which is regulated by its specific inhibitor,
plasminogen activator inhibitor-1 (PAI-1) [4, 5]. Also,Key words: mesothelial cells, simvastatin, tissue factor, fibrinolysis,
peritoneal dialysis, peritonitis. HMC produce the membrane-bound glycoprotein tissue
factor [6, 7], which initiates coagulation as it serves as a
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the peritoneal cavity, as they suppress the synthesis of (simvastatin, 10 mmol/L), phosphate-buffered saline (PBS)
t-PA and increase the expression of PAI-1 and tissue (MVA, 1 mol/L, pH 7.0), or ethanol (GG, 10 mmol/L)
factor in HMC [9]. and stored at –20C. Immediately before use, the com-
Recent work from our laboratory describes a specific pounds were diluted in incubation medium to the final
class of cholesterol-lowering drugs, 3-hydroxy-3-methyl- test concentration, whereby the final concentration of
glutaryl coenzyme A (HMG-CoA) reductase inhibitors DMSO did not exceed 0.03% (vol/vol). Hybond-N fil-
(statins), as effective agents to increase the fibrinolytic ters, Hyperfilm-MP, and deoxycytidine 5-(-32P) tri-
capacity of HMC. Using cultured HMC, we found that phosphate (3 Ci/mol) were obtained from Amersham
statins strongly increase the synthesis of t-PA and de- Pharmacia Biotech (Buckinghamshire, UK).
crease the expression of PAI-1. These actions of statins
Cell culture experimentswere reversed by mevalonic acid (MVA) and geranylger-
anyl pyrophosphate (GGPP) but not squalene, indicating HMC were isolated from the omental tissue of con-
that an inhibitory prenylated product rather than choles- senting patients undergoing elective surgery as described
terol-lowering per se is involved in this profibrinolytic previously [4] and the experimental protocol was ap-
activity of statins [10]. proved by the institutional committees of the Leiden
In addition to promoting the basal fibrinolytic capacity University Medical Center and TNO Prevention and
in mesothelial cells there is increasing evidence for anti- Health. HMC were grown in fibronectin-coated dishes
inflammatory activity of statins. In vitro as well as in in M199 supplemented with 20 mmol/L HEPES (pH
vivo experiments have demonstrated that statins down- 7.4), 2 mmol/L glutamine, 10% (vol/vol) human serum,
regulate the synthesis of inflammatory mediators [11, 12] 10% (vol/vol) newborn calf serum, ECGS (150 g/mL),
and suppress the expression of endotoxin- and thrombin- 5 IU/mL heparin, penicillin (100 IU/mL), and streptomy-
induced tissue factor in macrophages and endothelial cin (100 g/mL) at 37C in a 5% CO2/95% air atmo-
cells [13–15]. sphere. The medium was replaced every 2 to 3 days.
In this study, we investigated the anti-inflammatory po- Cells were subcultured with mild trypsinization (1 to 2
tential of simvastatin in tumor necrosis factor- (TNF-)– minutes), using trypsin/ethylenediaminetetraacetic acid
activated HMC. We demonstrate that simvastatin inhib- (EDTA) (0.5 g/L trypsin, 0.25 g/L EDTA), after which
its completely TNF-–induced tissue factor and PAI-1 the cells were replated with a split ratio of 1:3. Cells from
expression, while maintaining its t-PA synthesis–enhanc- omental tissue were pure mesothelial cells, as assessed by
ing effect. Furthermore, we provide a molecular explana- their uniform cobblestone appearance at confluence, by
tion for the anti-inflammatory action of simvastatin.
the absence of von Willebrand factor, and by the uniform
positive staining for cytokeratin-8 and -18 and for vimen-
METHODS tin [4]. For the experiments, confluent cultures were used
at the second or third passage. The day before the experi-Materials
ment, cells were incubated with M199 medium supple-M199 medium was obtained from Flow Laboratories
mented with 20 mmol/L HEPES (pH 7.4), 10% (vol/(Irvine, Scotland); tissue culture plastics were from Co-
vol) human serum, 2 mmol/L glutamine, and antibioticsstar (Cambridge, MA, USA). A crude preparation of
(incubation medium). None of the compounds tested hadendothelial cell growth supplement (ECGS) was pre-
an effect on cell viability, as tested by the MTT assaypared from bovine brain, as described by Maciag et al
(Roche Diagnostics, Almere, The Netherlands). Condi-[16]. Human serum was prepared from freshly collected
tioned media were obtained by incubating cells in 2 cm2blood of healthy donors, pooled, and stored at 4C. New-
dishes at 37C for 24 to 48 hours with 0.5 mL incubationborn calf serum was purchased from GIBCO (Grand
medium containing the appropriate concentration of theIsland, NY, USA) and was heat-inactivated (30 minutes
test compound or stock solvent. For incubation periodsat 56C) before use. Collagenase type II was from Worth-
longer than 24 hours, the medium was refreshed everyington (Freehold, NY, USA). Monoclonal antibodies
24 hours. Conditioned media were centrifuged to removeagainst cytokeratin-8 and -18 and against vimentin were
cells and cellular debris and samples were frozen ata gift from Dr. G. van Muijen (University of Nijmegen,
20C until use. Remaining cells were used for isolationThe Netherlands). Human recombinant TNF- was a
of RNA.gift from Dr. J. Tavernier (Biogent, Ghent, Belgium).
Simvastatin was obtained from Merck (Boom, Amster-
Assaysdam, The Netherlands), MVA was purchased from ICN
The assay of t-PA antigen was performed with the en-Biomedicals (Zoetermeer, The Netherlands), and gera-
zyme-linked immunosorbent assay (ELISA) Thrombo-nylgeraniol (GG) was from Sigma Chemical Co. (Zwijn-
nostika t-PA (Organon-Technika, Turnhout, Belgium),drecht, The Netherlands). Stock solutions of the com-
pounds were prepared in dimethyl sulfoxide (DMSO) which detects free t-PA and t-PA–PAI-1 complexes with
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equal efficiency. PAI-1 antigen was measured by an ELISA Technology, Breda, The Netherlands) supplemented
with 10% (vol/vol) fetal calf serum (FCS), 100 IU/mLkit (IMULYSE) obtained from Biopool (Umea˚, Sweden).
penicillin, and 100 g/mL streptomycin and were pre-
RNA isolation and Northern blotting treated with simvastatin for 24 hours. Suppression of
NF-B and AP-1 activity by statins was determined byTotal RNA was extracted from cells as described by
Chomczynski and Sacchi [17]. RNA samples were dis- transient transfection of 100 ng 3  NF-B-luciferase re-
porter plasmid [20] or 100 ng collagenase-5  12-o-tetra-solved in water and the RNA concentration in each
sample was determined spectrophotometrically. Equal decanol phorbol acetate (TRE) luciferase reporter plas-
mid [21] (both plasmids were kindly provided by Dr. A.amounts of RNA were analyzed for tissue factor and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Hausser and Dr. H. Wajant) per 1.2  105 cells using
the Fugene6 reagent (Roche Diagnostics, Almere, ThemRNA content by Northern blot hybridization as out-
lined before [5]. In short, RNA samples were subjected Netherlands). After transfection, the cells were again
incubated with simvastatin and stimulated after 5 hoursto gel electrophoresis in formaldehyde-agarose gels. Af-
ter electrophoresis, RNA was transferred to Hybond-N by adding TNF- (100 U/mL) as described in the figure
legends. Cells were harvested after an additional 17and hybridization was performed at 62C with 1 ng/mL
probe labeled by random prime labeling to approxi- hours’ incubation period for quantification of luciferase
activity using the dual luciferase reporter assay systemmately 2  108 cpm/g DNA. The membranes were
subsequently exposed to Amersham Hyperfilm-MP film (Promega, Leiden, The Netherlands) as described pre-
viously [19].with an intensifying screen at 80C. The intensities
of the signals were determined using a Fujix Bas 1000
Statisticsphosphoimager and expressed relative to the signal of
the GAPDH mRNA band. Data are given as means	 SD. Statistical analysis was
performed with the Mann-Whitney U test, and a P value
Nuclear extract preparation and Western blotting of less than 0.05 was considered significant.
HMC were washed with ice-cold PBS and nuclear cellu-
lar extracts were prepared in the presence of protease
RESULTS
inhibitors (PI) (Roche Diagnostics, Almere, The Nether-
The effect of simvastatin on the synthesis of t-PA andlands) as reported [18]. Prepared nuclear extracts were
PAI-1 in TNF-–stimulated HMCimmediately boiled in Laemmli electrophoresis buffer.
For sodium dodecyl sulfate-polyacrylamide gel electro- Figure 1 shows time- and concentration-dependent ef-
fects of simvastatin (1 to 5 mol/L) on t-PA and PAI-1phoresis (SDS-PAGE), equal amounts of proteins (20 g)
were electrophoresed as described [19] using a Minigel production in TNF-–stimulated HMC. Cells were incu-
bated for two consecutive periods of 24 hours with or with-system (BioRad Laboratories, Veenendaal, The Nether-
lands) and proteins were blotted onto Immobilon-P poly- out TNF- (50 U/mL) and/or simvastatin. With TNF-
only, t-PA production levels were already significantlyvinylidene fluoride transfer membranes (Millipore, Bed-
ford, MA, USA). Blots were blocked with 5% (weight/vol) decreased after 24 hours (Fig. 1A) with the effect becom-
ing maximal after 48 hours (from 5.4	 0.4 ng/105 cells toskim milk powder (Merck, Amsterdam, The Netherlands)
diluted in 20 mmol/L Tris (pH 7.4), 55 mmol/L NaCl, 0.1% 1.3	 0.1 ng/105 cells, N
 3) (Fig. 1B). In the presence of
simvastatin, t-PA synthesis in control cells and TNF-–(vol/vol) Tween-20, and developed with primary antibodies
p50–NF-B (Santa Cruz [sc] 1190), p65–NF-B (sc 8008), treated cells, time- and dose-dependently increased, reach-
ing 2.4-fold (control) and 2.9-fold (TNF-) higher t-PAc-jun (sc 45), or c-fos (sc 447), and compatible horseradish
peroxidase–conjugated secondary antibodies. Histone H1 levels after 24 hours and 5.8-fold (control) and 7.7-fold
(TNF-) higher t-PA levels after 48 hours at 5 mol/Lantibodies were used to control equal loading. All anti-
bodies used were obtained from Santa Cruz (Heerhugo- simvastatin, respectively. After 48 hours, the t-PA produc-
tion in TNF-–treated cells in the presence of 5 mol/Lwaard, The Netherlands) and they were diluted in 20
mmol/L Tris (pH 7.4), 55 mmol/L NaCl, 0.1% (vol/vol) simvastatin was about 1.9-fold higher than that of control
cells without TNF- and simvastatin. The t-PA stimula-Tween-20, 5% (weight/vol) bovine serum albumin (BSA).
The Super Signal West Dura Extended Duration Sub- tory effect of simvastatin became already significant at
1mol/L with increases of 3.6-fold and 4.1-fold in controlstrate (Pierce, St. Augustin, Germany) and the lumines-
cent image workstation (Roche Diagnostics, Almere, and TNF-–treated cells, respectively (Fig. 1B). These
results indicate that the extent of the t-PA–stimulatoryThe Netherlands) were used for visualization.
effect in control and TNF-–treated cells is very compa-
Plasmids, transient transfection and luciferase assay rable, but that simvastatin is unable to block the t-PA–
suppressing effect of TNF- per se.Human fibrosarcoma HT1080 cells were cultured in
Dulbecco’s modified Eagles’s medium (DMEM) (Life As shown in Figure 1C, TNF- induced an increase
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Fig. 1. Time- and concentration-dependent
effect of simvastatin on tissue-type plasmino-
gen activator (t-PA) and plasminogen activa-
tor inhibitor-1 (PAI-1) production in tumor
necrosis factor- (TNF-)–activated human
peritoneal mesothelial cells (HMC). HMC
were incubated for two consecutive periods
of 24 hours with TNF- (50 U/mL) () or
without (), and with different concentrations
of simvastatin. The conditioned media were
analyzed for t-PA (A and B) and PAI-1 (C and
D ) antigens. Results shown are production
levels over the first (A and C) and second
(B and D) 24-hour incubation period and are
mean	 SD of three independent experiments
performed in triplicate. *Significant difference
(P  0.05) with corresponding control values.
in PAI-1 synthesis after 24 hours, which was further in-
creased after 48 hours (Fig. 1D), when TNF- induced
a 1.5-fold increase in PAI-1 synthesis (1405 	 153 ng/105
cells under control conditions versus 2098 	 236 ng/105
cells with TNF-, N 
 3) (Fig. 1D). PAI-1 production
in both control and TNF-–treated cells was dose-depen-
dently suppressed in the presence of simvastatin, reach-
ing 1.1-fold (control) and 1.3-fold (TNF-) lower PAI-1
concentrations after 24 hours and 3.4-fold (control) and
4.0-fold (TNF-) lower PAI-1 concentrations after 48
hours, respectively, at 5 mol/L simvastatin. As seen for
t-PA, the PAI-1–suppressing effects of simvastatin were
already significant at 1 mol/L (1.6-fold and 1.5-fold
lower PAI-1 concentrations in control and TNF-–
treated cells, respectively). In contrast to t-PA, however,
increasing simvastatin concentrations not only decreased
basal PAI-1 synthesis, but also suppressed the TNF-
effect itself.
To evaluate whether simvastatin can also quench the
effect of TNF- on t-PA and PAI-1 synthesis when it is
added after TNF- administration, HMC were incubated
with TNF- for three consecutive periods of 24 hours
and simvastatin (1 mol/L) was only present during the
second and the third incubation period. Figure 2 illus-
trates that simvastatin also efficiently enhances t-PA syn-
Fig. 2. Effect of simvastatin on tissue-type plasminogen activator (t-PA) thesis and decreases PAI-1 synthesis when simvastatin is
and plasminogen activator inhibitor-1 (PAI-1) production in human
added after TNF- administration, indicating that statinsperitoneal mesothelial cells (HMC) pretreated with tumor necrosis
factor- (TNF-). HMC were incubated for three consecutive periods of are not only effective in a preventive way, but also after
24 hours with TNF- (10 U/mL) (), or without (), while simvastatin onset of the inflammatory state.(1 mol/L) was present only during the second and third incubation
The simvastatin effects on t-PA and PAI-1 synthesisperiod. The conditioned media were analyzed for t-PA (A ) and PAI-1
(B ) antigens. Results shown are production levels over the third 24-hour in both control and TNF-–activated HMC could be
incubation period and are mean	 SD of three independent experiments completely overcome by addition of MVA (100 mol/L)performed in triplicate. *Significant difference (P  0.05) with corre-
sponding control values. or GG (10mol/L) to the cells (data not shown), pointing
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Fig. 3. Time-course of tissue factor (TF) expression in tumor necrosis
factor- (TNF-)–stimulated human peritoneal mesothelial cells (HMC)
incubated with or without simvastatin (Sim). HMC were incubated for
24 hours and 48 hours with () or without () 1 mol/L simvastatin
for TF mRNA analysis. One hour before the end of the incubation
TNF- (10 U/mL) () or phosphate-buffered saline (PBS) () was
added to the cells. Total RNA was isolated and analyzed by Northern
blot hybridization for TF and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) mRNA. The experiment shown is representative for
three independent experiments (A ). The signals for TF mRNA were
quantified by densitometry and adjusted for corresponding GAPDH
mRNA signals. The amount of TF mRNA at the different time points
is expressed relative to that found at t 
 0 (B ). The results shown in
(B) are means 	 SD of three independent experiments. Symbols are:
() TNF-; () TNF-. *Significant difference (P  0.05) with
control values at t 
 0.
to a role of a prenylated product rather than cholesterol- can further down-regulate tissue factor expression, we
incubated HMC for 48 hours with 1, 2.5, and 5 mol/Llowering per se in the modulatory action of simvastatin.
simvastatin. As shown in Figure 4, 1 mol/L simvastatin
Time course and concentration dependency of the was already sufficient to completely abrogate the TNF-
effect of simvastatin on TNF-–induced tissue factor effect; at higher simvastatin concentrations there was a
expression in HMC further decrease in tissue factor mRNA levels (at 5
mol/L, suppression to 20% of levels under control con-To evaluate the effect of simvastatin on mesothelial
ditions was seen).cell tissue factor expression RNA was isolated from the
incubated cells and analyzed by Northern blotting. HMC
MVA and GG reverse the inhibitory effect ofwere treated for 24 hours or 48 hours with simvastatin
simvastatin on tissue factor expressionand 1 hour before the end of the incubation, 10 U/mL
TNF- was added to the medium. Figure 3 shows a To assess the signal transduction pathway underlying
the simvastatin effect on tissue factor expression inrepresentative time course of the effect of 1 mol/L sim-
vastatin on tissue factor expression in HMC. Suppression HMC, we investigated the role of two intermediates of
the cholesterol biosynthesis pathway, namely MVA, theof tissue factor mRNA levels of control and TNF-–
stimulated cells by simvastatin became already visible product of HMG CoA reductase, and GGPP, an MVA-
derived intermediate in the cholesterol biosynthesisafter 24 hours’ incubation with simvastatin, but a further
suppression was achieved by incubating cells for 48 hours pathway. We have previously shown that both products
are involved in the stimulatory effect of simvastatin onwith the statin. Basal tissue factor expression was sup-
pressed to 32% of control values. The stimulatory effect the fibrinolytic system of mesothelial cells, whereas inter-
mediates further downstream in the cholesterol biosyn-of TNF-, which induced a 1.7-fold increase in tissue
factor mRNA levels, was completely overcome by sim- thesis pathway (notably, squalene) did not influence
t-PA and PAI-1 expression [10]. As illustrated in Figurevastatin, resulting in a suppression to 22% of values
obtained in TNF-–stimulated cells. 5, addition of MVA (100 mol/L) to the cells completely
reversed the effect of 1 mol/L simvastatin on tissueTo study whether higher simvastatin concentrations
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tional activity. NF-B– and AP-1–dependent reporter
gene activity was measured in the fibrosarcoma cell line
HT1080, as these cells have a greater efficiency and re-
producibility of transfection, but resemble HMC in their
tissue factor expression [26]. HT1080 cells were tran-
siently transfected with a collagenase-TRE-luciferase re-
porter (AP-1 responsive) or a 3  NF-B–luciferase
reporter (NF-B responsive), treated with increasing
doses of simvastatin (0.3, 1, and 3mol/L) and stimulated
with TNF- (100 U/mL). NF-B– and AP-1–dependent
luciferase activity was 2.1-fold and 1.7-fold increased in
response to TNF-, respectively (Fig. 6A and Fig. 7A).
Treatment with simvastatin reduced both NF-B– and
AP-1–dependent luciferase activity in a concentration-
dependent manner, with almost complete inhibition ob-
served at 1 mol/L simvastatin (Fig. 6A and Fig. 7A).
To evaluate whether the inhibitory effects of simva-
statin on NF-B and AP-1 activity are related to the
nuclear concentrations of the respective transcription
factors, we analyzed p50–NF-B, p65–NF-B, and the
AP-1 constituents c-fos and c-jun in nuclear HT1080 and
mesothelial cell extracts. To that end, HT1080 cells and
HMC were incubated for 48 hours with 1 mol/L simva-
statin or control medium and stimulated with TNF- (10
U/mL) for 1 hour. Western blot analysis of the HMC
nuclear extracts revealed that the nuclear concentrations
of p50–NF-B and p65–NF-B were increased by TNF-
Fig. 4. Effect of increasing concentrations of simvastatin (Sim) on tis- and that simvastatin prevented this increase (Fig. 6B).sue factor (TF) expression in tumor necrosis factor- (TNF-)–stimulated
Nuclear c-fos and c-jun levels were already high underhuman peritoneal mesothelial cells (HMC). HMC were incubated for 48
hours with increasing concentrations of simvastatin for mRNA analysis. control conditions and were not further increased upon
One hour before the end of the incubation, TNF- (10 U/mL) () or stimulation with TNF-. Treatment with simvastatin,phosphate-buffered saline (PBS) () was added to the cells. Total RNA
however, markedly decreased the nuclear concentrationswas isolated and analyzed by Northern blot hybridization for TF and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. The of c-jun and c-fos, both in the absence and presence of
experiment shown is representative for three independent experiments
TNF- (Fig. 7B). Similar results were obtained in HT1080(A ). The signals for TF mRNA were quantified by densitometry and
adjusted for corresponding GAPDH mRNA signals. The amount of cells, where simvastatin (1 mol/L) also efficiently de-
TF mRNA at the different simvastatin concentrations is expressed creased the concentrations of p50–NF-B, p65–NF-B,
relative to that found at control conditions (B). The results shown in
c-fos and c-jun proteins in nuclear extracts of control(B) are means 	 SD of three independent experiments. Symbols are:
() TNF-; () TNF-. *Significant difference (P  0.05) with and TNF-–activated cells (data not shown).
corresponding control values.
DISCUSSION
Peritonitis remains one of the leading causes of mor-
factor mRNA expression. GG, which is involved in the bidity and patient dropout from peritoneal dialysis ther-
posttranslational modification of diverse signaling pro- apy [27]. Infections induce an inflammatory response
teins [22–24], completely mimicked the effect of MVA of the serosal inner abdominal surfaces resulting in the
on simvastatin-treated cells (Fig. 5). These results indi- generation of a serofibrinous exudate and peritoneal fi-
cate that simvastatin down-regulates tissue factor expres- brin deposition. Depending on the peritoneal fibrinolytic
sion through intervention in the MVA-GGPP pathway. capacity, the fibrin deposits are lysed, which promotes
healing, or become organized, which can lead to the
Simvastatin reduces NF-B and AP-1 activity development of adhesions and peritoneal fibrosis [3]. As
TNF-–induced tissue factor expression is known to mesothelial cells present the most numerous cell popula-
be largely controlled at the transcriptional level through tion in the peritoneal cavity, they are supposed to play a
NF-B and AP-1 binding sites in the tissue factor promo- major role in the balance of procoagulant and fibrinolytic
tor [25]. Reduced tissue factor gene transcription sug- activity by producing tissue factor as well as t-PA and
its specific inhibitor, PAI-1 [4]. Recently, we describedgests that statins may reduce NF-B and AP-1 transcrip-
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Fig. 5. Inhibition of the simvastatin (Sim) effect on tissue factor (TF)
expression by mevalonic acid (MVA) and geranylgeraniol (GG) in
human peritoneal mesothelial cells (HMC). HMC were incubated for
48 hours with () or without () 1 mol/L simvastatin in the presence
or absence of 100 mol/L MVA or 10 mol/L GG for TF mRNA
analysis. One hour before the end of the incubation, tumor necrosis
factor- (TNF-) (10 U/mL) () or phosphate-buffered saline (PBS)
() was added to the cells. Total RNA was isolated and analyzed by
Northern blot hybridization for TF and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA. The experiment shown is represen-
tative for three independent experiments (A ). The signals for TF mRNA
were quantified by densitometry and adjusted for corresponding
GAPDH mRNA signals. The amount of TF mRNA under the different
experimental conditions is expressed relative to that found under control
conditions. The results shown in (B) are means 	 SD of three indepen-
dent experiments. Symbols are: ()TNF-; ()TNF-. *Significant
difference (P  0.05) with control values.
the HMG-CoA reductase inhibitor simvastatin as an ef- kin-1 (IL-1), and lipopolysaccharide (LPS). TNF-, which
we have used as a representative cytokine in this study,fective agent to increase the basal fibrinolytic capacity
of mesothelial cells as it strongly increases the synthesis enhances tissue factor transcription through activating
the transcription factors NF-B and/or AP-1 [25, 32]. Inof t-PA and decreases the expression of PAI-1 [10]. In
this study we investigated the effect of simvastatin under our experiments, simvastatin diminished basal and TNF-–
induced increases of subunits of these transcription fac-inflammatory conditions and we report that simvastatin
enhances the fibrinolytic capacity and suppresses the tors (i.e., p50–NF-B, p65–NF-B, c-jun and c-fos) in
mesothelial nuclear extracts and prevented the activationprocoagulant activity of TNF-–stimulated HMC.
Simvastatin completely prevented the TNF-–induced of the corresponding promoter constructs. Recently, it
has been shown that another HMG-CoA reductase in-effect on tissue factor and PAI-1 expression and concom-
itantly enhanced t-PA synthesis in HMC. The action of hibitor, atorvastatin, attenuated NF-B activation in vas-
cular smooth muscle cells by stabilizing its cytosolic in-simvastatin was also seen when it was added after TNF-
administration. The effects of simvastatin were time- and hibitor IB. IB binds NF-B, thereby preventing its
nuclear translocation and thus NF-B–dependent geneconcentration-dependent and were prevented by MVA
and GG, indicating that the effects on t-PA, PAI-1, and transcription [33]. Possibly, simvastatin acts via the same
mechanism in mesothelial cells.tissue factor synthesis are mediated through geranylgera-
nylated proteins. The isoprenoid GGPP plays a central The finding that simvastatin completely suppresses
TNF-–induced PAI-1 and tissue factor expression androle in many signaling events by posttranslationally mod-
ifying signaling proteins, such as the GTP-binding pro- effectively enhances t-PA synthesis may have clinical
implications. After the onset of peritonitis simvastatinteins Rho and Ras [28–31].
Tissue factor expression is controlled largely at the might serve as a useful drug to counteract the transient
hypofibrinolytic state in the peritoneal cavity during in-transcriptional level and its promoter contains binding
sites for the transcription factors NF-B/Rel and AP-1 flammatory episodes. Recently, high levels of PAI-1 were
detected in the effluent of peritoneal dialysis patients[25]. Tissue factor expression can be rapidly induced by
specific inflammatory mediators, such as TNF-, interleu- with peritonitis [34], which mainly account for the imbal-
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Fig. 6. The effect of simvastatin on the activation of nuclear factor kappa B (NF-B). (A ) HT1080 fibrosarcoma cells were pretreated for 24
hours with simvastatin (0.3, 1, or 3 mol/L) before transient transfection with a 3  NF-B-luciferase reporter plasmid. After transfection, the
cells were incubated for an additional 24 hours with simvastatin (0.3, 1, 3 mol/L) and for 17 hours with tumor necrosis factor- (TNF-) (100
U/mL) () or phosphate-buffered saline (PBS) (). Results are given as means 	 SD of three independent experiments. Symbols are: ()
TNF-; () TNF-. *P  0.05 compared with control. (B ) HMC were incubated for 48 hours with () or without () 1 mol/L simvastatin
(Sim). One hour before the end of the incubation period, tumor necrosis factor- (TNF-) (10 U/mL) () or phosphate-buffered saline (PBS)
() was added to the cells. Nuclear extracts were prepared and analyzed for p50–NF-B and p65–NF-B expression by Western blotting. Histone
H1 levels are shown as a control. The experiment shown is representative for three independent experiments.
Fig. 7. The effect of simvastatin on the activation of activator protein-1 (AP-1). (A ) HT1080 fibrosarcoma cells were pretreated for 24 hours with
simvastatin (Sim) (0.3, 1, or 3 mol/L) before transient transfection with a collagenase-5  12-o-tetradecanol phorbol acetate (TRE)-luciferase
reporter plasmid. After transfection, the cells were incubated for an additional 24 hours with simvastatin (0.3, 1, 3 mol/L) and for 17 hours with
tumor necrosis factor- (TNF-) (100 U/mL) () or phosphate-buffered saline (PBS) (). Results are given as means 	 SD of three independent
experiments. Symbols are: () TNF-; () TNF-. *P  0.05 compared with control. (B ) Human peritoneal mesothelial cells (HMC) were
incubated for 48 hours with () or without () 1 mol/L simvastatin; 1 hour before the end of the incubation, TNF- (10 U/mL) () or PBS
() was added to the cells. Nuclear extracts were prepared and analyzed for c-jun and c-fos expression by Western blotting. Histone H1 levels
are shown as a control. The experiment shown is representative for three independent experiments.
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